



Blueprint Medicines Files Registration Statement for Proposed Initial Public Offering

Cambridge, Mass., March 23, 2015 – Blueprint Medicines Corporation, a leader in discovering and developing highly selective kinase drugs for genomically defined diseases, today announced it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Blueprint Medicines intends to list its common stock under the symbol “BPMC” on The NASDAQ Global Market.

Goldman, Sachs & Co. and Cowen and Company, LLC will act as joint book-running managers for the offering. JMP Securities will serve as a co-manager for the offering. Wedbush PacGrow will also serve as a co-manager for the offering.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Goldman, Sachs & Co. by mail at 200 West Street, New York, New York 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com, and from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (631) 274-2806, or by fax at (631) 254-7140.

Contact:

Investor Relations:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
beth@sternir.com

Media:
Beth Keshishian
inVentiv Health PR
212-229-8417
beth.keshishian@inventivhealth.com